These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34321280)

  • 1. A Phase I Study of the Combination of Pexidartinib and Sirolimus to Target Tumor-Associated Macrophages in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors.
    Manji GA; Van Tine BA; Lee SM; Raufi AG; Pellicciotta I; Hirbe AC; Pradhan J; Chen A; Rabadan R; Schwartz GK
    Clin Cancer Res; 2021 Oct; 27(20):5519-5527. PubMed ID: 34321280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
    Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
    Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
    Gelderblom H; Wagner AJ; Tap WD; Palmerini E; Wainberg ZA; Desai J; Healey JH; van de Sande MAJ; Bernthal NM; Staals EL; Peterfy CG; Frezza AM; Hsu HH; Wang Q; Shuster DE; Stacchiotti S
    Cancer; 2021 Mar; 127(6):884-893. PubMed ID: 33197285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
    Tap WD; Gelderblom H; Palmerini E; Desai J; Bauer S; Blay JY; Alcindor T; Ganjoo K; Martín-Broto J; Ryan CW; Thomas DM; Peterfy C; Healey JH; van de Sande M; Gelhorn HL; Shuster DE; Wang Q; Yver A; Hsu HH; Lin PS; Tong-Starksen S; Stacchiotti S; Wagner AJ;
    Lancet; 2019 Aug; 394(10197):478-487. PubMed ID: 31229240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA.
    Dharmani C; Fofah O; Wang E; Salas M; Wooddell M; Tu N; Tse J; Near A; Tinoco G
    Future Oncol; 2024; 20(16):1079-1097. PubMed ID: 38380590
    [No Abstract]   [Full Text] [Related]  

  • 6. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E; Longhi A; Donati DM; Staals EL
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.
    Wesolowski R; Sharma N; Reebel L; Rodal MB; Peck A; West BL; Marimuthu A; Severson P; Karlin DA; Dowlati A; Le MH; Coussens LM; Rugo HS
    Ther Adv Med Oncol; 2019; 11():1758835919854238. PubMed ID: 31258629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors.
    Lewis JH; Gelderblom H; van de Sande M; Stacchiotti S; Healey JH; Tap WD; Wagner AJ; Pousa AL; Druta M; Lin CC; Baba HA; Choi Y; Wang Q; Shuster DE; Bauer S
    Oncologist; 2021 May; 26(5):e863-e873. PubMed ID: 33289960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
    Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
    Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
    Alsayadi YMMA; Chawla PA
    Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT).
    Tap W
    Future Oncol; 2020 Sep; 16(25):1875-1878. PubMed ID: 32755241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).
    Kim A; Lu Y; Okuno SH; Reinke D; Maertens O; Perentesis J; Basu M; Wolters PL; De Raedt T; Chawla S; Chugh R; Van Tine BA; O'Sullivan G; Chen A; Cichowski K; Widemann BC
    Sarcoma; 2020; 2020():5784876. PubMed ID: 32089640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I/II Investigation of Safety and Efficacy of Nivolumab and
    Gordon EM; Angel NL; Omelchenko N; Chua-Alcala VS; Moradkhani A; Quon D; Wong S
    Anticancer Res; 2023 May; 43(5):1993-2002. PubMed ID: 37097693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.
    Yin O; Wagner AJ; Kang J; Knebel W; Zahir H; van de Sande M; Tap WD; Gelderblom H; Healey JH; Shuster D; Stacchiotti S
    J Clin Pharmacol; 2021 Apr; 61(4):480-492. PubMed ID: 33043474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
    Gelderblom H; de Sande MV
    Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor.
    Lin F; Jacqueline Kwong W; Pan I; Ye X; Dai D; Tap W
    Oncologist; 2024 Apr; 29(4):e535-e543. PubMed ID: 37874926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.
    Van De Sande M; Tap WD; Gelhorn HL; Ye X; Speck RM; Palmerini E; Stacchiotti S; Desai J; Wagner AJ; Alcindor T; Ganjoo K; Martín-Broto J; Wang Q; Shuster D; Gelderblom H; Healey JH
    Acta Orthop; 2021 Aug; 92(4):493-499. PubMed ID: 33977825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pexidartinib Upfront in a Case of Tenosynovial Giant Cell Tumor: Proof of Concept for a Treatment Paradigm Shift.
    Palmerini E; Peta G; Tuzzato G
    Oncol Ther; 2024 Dec; 12(4):833-841. PubMed ID: 39155359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.